2026 Q3 Portfolio Activity
In 2026 Q3, Vivo Capital, LLC maintained a portfolio of 55 distinct positions. The most significant new addition was Entera Bio Ltd, now representing 3.92% of the total fund value. They heavily accumulated shares in Faeth Therapeutics Inc, increasing the position by 17.0%. Conversely, Vivo Capital, LLC completely exited their position in Sinovac Biotech Ltd..
Position History
hover any row below to update
Loading…
Total Positions
55
Quarter
2026 Q3
Top Holding
PRAX (8.7%)
Top 10 Concentration
51.3%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 55
Vivo Capital, LLC Full Holdings List — 2026 Q3
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
PRAX
Praxis Precisio...
|
Healthcare | 8.69% | 8.29% |
#1
1
Prev: #2
|
6.5 |
—
|
no change | no change |
P
S
|
271,116 | $78,957,113 |
$148.26
+109.7%
|
2025 Q2 | 13F Filing | 2026-09-30 | 2026-11-13 | ||
|
TRVI
Trevi Therapeut...
|
Healthcare | 6.67% | 8.68% |
#2
1
Prev: #1
|
4.7 |
—
|
-864,985 | -17.0% |
P
S
|
4,229,683 | $60,569,061 | 2024 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
ERAS
Erasca Inc
|
Healthcare | 6.49% | 6.90% |
#3
Prev: #3
|
4.1 |
—
|
-106,793 | -2.6% |
P
S
|
4,020,619 | $58,942,275 | 2024 Q2 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
AVBP
Arrivent BioPha...
|
Healthcare | 5.95% | 5.34% |
#4
Prev: #4
|
4.9 |
—
|
105,007 | 6.2% |
P
S
|
1,787,104 | $54,113,509 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
ABVX
Abivax SA
|
Healthcare | 4.52% | 5.05% |
#5
Prev: #5
|
3.3 |
—
|
no change | no change |
P
S
|
414,899 | $41,083,299 | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
ENTX
Entera Bio Ltd
|
Healthcare | 3.92% | — |
#6
Prev: #—
|
5.1 |
—
|
12,254,901 | — |
NEW
|
12,254,901 | $35,661,762 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
ACRS
Aclaris Therape...
|
Healthcare | 3.88% | 3.23% |
#7
4
Prev: #11
|
2.6 |
—
|
no change | no change |
P
S
|
6,694,637 | $35,213,791 | 2016 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
ANRO
Alto Neuroscien...
|
Healthcare | 3.82% | 2.91% |
#8
6
Prev: #14
|
3.5 |
—
|
151,057 | 12.5% |
P
S
|
1,359,915 | $34,718,630 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
TNGX
Tango Therapeut...
|
Healthcare | 3.79% | 3.94% |
#9
3
Prev: #6
|
2.5 |
—
|
no change | no change |
P
S
|
1,379,769 | $34,425,237 | 2025 Q2 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
CRVS
Corvus Pharmace...
|
Healthcare | 3.56% | 3.83% |
#10
3
Prev: #7
|
2.4 |
—
|
no change | no change |
P
S
|
2,805,816 | $32,323,000 | 2024 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
LBRX
LB Pharmaceutic...
|
Healthcare | 3.38% | 2.37% |
#11
7
Prev: #18
|
2.4 |
—
|
no change | no change |
P
S
|
800,000 | $30,704,000 | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
KRSA
Korsana Bioscie...
|
Healthcare | 3.09% | — |
#12
Prev: #—
|
4.7 |
—
|
877,020 | — |
NEW
|
877,020 | $28,064,640 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
BLSM
Blossomhill The...
|
Healthcare | 3.06% | — |
#13
Prev: #—
|
4.7 |
—
|
1,493,740 | — |
NEW
|
1,493,740 | $27,843,314 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
SNSE
Faeth Therapeut...
|
Healthcare | 2.76% | 1.65% |
#14
9
Prev: #23
|
3.1 |
—
|
122,556 | 17.0% |
P
S
|
844,576 | $25,117,690 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
CAMP
CAMP4 Therapeut...
|
Healthcare | 2.48% | 1.69% |
#15
7
Prev: #22
|
3.5 |
—
|
1,337,543 | 31.5% |
P
S
|
5,584,111 | $22,559,808 | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
ACHV
Achieve Life Sc...
|
Healthcare | 2.45% | 1.64% |
#16
8
Prev: #24
|
2.0 |
—
|
no change | no change |
P
S
|
2,751,032 | $22,255,849 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
SABS
SAB Biotherapeu...
|
Healthcare | 2.41% | 2.60% |
#17
1
Prev: #16
|
1.5 |
—
|
-384,898 | -5.3% |
P
S
|
6,915,011 | $21,920,585 | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
DBVT
DBV Technologie...
|
Healthcare | 2.39% | 2.76% |
#18
3
Prev: #15
|
2.0 |
—
|
no change | no change |
P
S
|
1,844,758 | $21,694,354 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
DRUG
Bright Minds Bi...
|
Healthcare | 2.29% | 3.57% |
#19
11
Prev: #8
|
0.9 |
—
|
-139,293 | -25.0% |
P
S
|
417,879 | $20,818,732 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
DSGN
Design Therapeu...
|
Healthcare | 2.23% | 2.13% |
#20
Prev: #20
|
1.9 |
—
|
no change | no change |
P
S
|
1,612,903 | $20,274,191 | 2021 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
ANTX
AN2 Therapeutic...
|
Healthcare | 1.85% | 1.39% |
#21
5
Prev: #26
|
1.7 |
—
|
no change | no change |
P
S
|
3,153,640 | $16,777,365 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
MLTX
Moonlake Immuno...
|
Healthcare | 1.80% | 2.49% |
#22
5
Prev: #17
|
1.7 |
—
|
no change | no change |
P
S
|
1,400,000 | $16,380,000 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
NERV
Minerva Neurosc...
|
Healthcare | 1.59% | 2.19% |
#23
4
Prev: #19
|
1.6 |
—
|
no change | no change |
P
S
|
4,322,747 | $14,481,202 | 2016 Q2 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
ODTX
Odyssey Therape...
|
Healthcare | 1.41% | 0.98% |
#24
5
Prev: #29
|
1.6 |
—
|
no change | no change |
P
S
|
575,000 | $12,776,500 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
ORIC
Oric Pharmaceut...
|
Healthcare | 1.37% | 1.83% |
#25
4
Prev: #21
|
0.5 |
—
|
-924,394 | -50.0% |
P
S
|
924,392 | $12,451,560 | 2023 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
EPRX
Eupraxia Pharma...
|
Healthcare | 1.35% | 0.81% |
#26
4
Prev: #30
|
1.5 |
—
|
no change | no change |
P
S
|
1,350,000 | $12,285,000 | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
VOR
Vor Biopharma I...
|
Healthcare | 1.16% | — |
#27
Prev: #—
|
4.0 |
—
|
550,358 | — |
NEW
|
550,358 | $10,500,831 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
EDIT
Editas Medicine...
|
Healthcare | 1.01% | 1.05% |
#28
1
Prev: #27
|
1.4 |
—
|
no change | no change |
P
S
|
3,555,250 | $9,136,993 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
SRZN
Surrozen Inc
|
Healthcare | 0.92% | 0.62% |
#29
6
Prev: #35
|
1.4 |
—
|
no change | no change |
P
S
|
260,000 | $8,366,800 | 2025 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
DYN
Dyne Therapeuti...
|
Healthcare | 0.91% | 3.16% |
#30
18
Prev: #12
|
0.4 |
—
|
-1,043,064 | -67.0% |
P
S
|
514,402 | $8,287,016 | 2020 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
AURA
Aura Bioscience...
|
Healthcare | 0.81% | 0.76% |
#31
3
Prev: #34
|
1.3 |
—
|
no change | no change |
P
S
|
1,166,667 | $7,326,669 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
CUE
Cue Biopharma I...
|
Healthcare | 0.80% | — |
#32
Prev: #—
|
3.8 |
—
|
280,057 | — |
NEW
|
280,057 | $7,245,075 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
MNPR
Monopar Therape...
|
Healthcare | 0.79% | 0.77% |
#33
Prev: #33
|
1.3 |
—
|
no change | no change |
P
S
|
90,500 | $7,210,135 | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
MSLE
Satellos Biosci...
|
Healthcare | 0.76% | 0.58% |
#34
3
Prev: #37
|
1.3 |
—
|
no change | no change |
P
S
|
813,666 | $6,916,161 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
OLMA
Olema Pharmaceu...
|
Healthcare | 0.64% | 0.77% |
#35
3
Prev: #32
|
1.3 |
—
|
no change | no change |
P
S
|
671,843 | $5,804,724 | 2020 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
PEPG
Pepgen Inc
|
Healthcare | 0.62% | 0.38% |
#36
3
Prev: #39
|
1.2 |
—
|
no change | no change |
P
S
|
2,325,000 | $5,626,500 | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
OKUR
Onkure Therapeu...
|
Healthcare | 0.58% | 0.80% |
#37
6
Prev: #31
|
1.2 |
—
|
no change | no change |
P
S
|
1,927,710 | $5,253,010 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
N/A
Attovia Therape...
|
|
Unknown | 0.57% | — |
#38
Prev: #—
|
3.7 |
—
|
300,000 | — |
NEW
|
300,000 | $5,142,000 | — | 13F Filing | 2026-09-30 | 2026-11-13 | ||
|
ADRX
ADARx Pharmaceu...
|
Healthcare | 0.56% | — |
#39
Prev: #—
|
3.7 |
—
|
255,158 | — |
NEW
|
255,158 | $5,087,851 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
TENX
Tenax Therapeut...
|
Healthcare | 0.52% | 3.32% |
#40
30
Prev: #10
|
1.2 |
—
|
no change | no change |
P
S
|
2,500,000 | $4,725,000 | 2024 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
VALN
Valneva SE
|
Healthcare | 0.52% | 0.36% |
#41
1
Prev: #40
|
1.2 |
—
|
no change | no change |
P
S
|
763,199 | $4,720,386 | 2021 Q2 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
AVTX
Avalo Therapeut...
|
Healthcare | 0.46% | 0.46% |
#42
4
Prev: #38
|
1.2 |
—
|
no change | no change |
P
S
|
275,000 | $4,215,750 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
CMPX
Compass Therape...
|
Healthcare | 0.39% | 1.55% |
#43
18
Prev: #25
|
0.2 |
—
|
-4,333,513 | -55.9% |
P
S
|
3,423,547 | $3,560,489 | 2021 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
SERA
Sera Prognostic...
|
Healthcare | 0.38% | 0.27% |
#44
3
Prev: #41
|
1.2 |
—
|
no change | no change |
P
S
|
1,650,440 | $3,449,420 | 2021 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
TIL
Instil Bio Inc
|
Healthcare | 0.23% | 0.21% |
#45
2
Prev: #43
|
1.1 |
—
|
no change | no change |
P
S
|
292,743 | $2,119,459 | 2023 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
INM
InMed Pharmaceu...
|
Healthcare | 0.12% | 0.11% |
#46
2
Prev: #44
|
0.5 |
—
|
26,497 | 3.3% |
P
S
|
824,874 | $1,121,829 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
BOLT
Bolt Biotherape...
|
Healthcare | 0.03% | 0.03% |
#47
2
Prev: #45
|
1.0 |
—
|
no change | no change |
P
S
|
72,414 | $266,484 | 2021 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
KTTA
Pasithea Therap...
|
Healthcare | 0.02% | 0.02% |
#48
2
Prev: #46
|
0.5 |
—
|
-92,675 | -19.9% |
P
S
|
372,796 | $183,788 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
DTIL
Precision Biosc...
|
Healthcare | 0.00% | 0.00% |
#49
2
Prev: #47
|
1.0 |
—
|
no change | no change |
P
S
|
4,675 | $29,266 | 2024 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
JSPR
Jasper Therapeu...
|
Healthcare | 0.00% | — |
#50
Prev: #—
|
3.5 |
—
|
5,364 | — |
NEW
|
5,364 | $3,693 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 |
Showing 1-50 of 55 holdings